<DOC>
	<DOCNO>NCT00746811</DOCNO>
	<brief_summary>The objective study assess effect 4 g/d P-OM3 , compare placebo , LDL-C aspect fast lipid profile subject primary hypercholesterolemia .</brief_summary>
	<brief_title>Trial Assess Effects P-OM3 LDL-C Subjects With Primary Hypercholesterolemia</brief_title>
	<detailed_description>This trial utilize randomize , double-blind , two-period crossover design . At Visit 2 ( Week 0 ) , subject meet entry criterion randomize one two treatment sequence : placebo P-OM3 first 6 week phase follow study product receive first phase ( P-OM3 placebo ) second 6 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Men woman , age 1879 inclusive Fasting , untreated lowdensity lipoprotein cholesterol ( LDLC ) level borderline high high range Fasting , untreated triglyceride ( TG ) level normal range Provide write informed consent authorization protect health information CHD CHD risk equivalent Pregnancy Use lipid alter medication stop Body mass index 45 kg per square meter Allergy sensitivity omega3 fatty acid Certain muscle , liver , kidney , lung gastrointestinal condition Poorly control hypertension Certain medication Active cancer treat within prior 2 year ( except nonmelanoma skin cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>omega 3</keyword>
</DOC>